Neurocrine (NBIX) Stock Forecast & Price Target

Compare

1,554 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

20 Buy

3 Hold

0 Sell

Based on 23 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$177.18

▲(38.01% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $177.18 with a high forecast of $204.00 and a low forecast of $140.00. The average price target represents a 38.01% change from the last price of $128.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","130":"$130","155":"$155","180":"$180","205":"$205"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":204,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$204.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":177.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$177.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$140.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,130,155,180,205],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.63,142.73538461538462,147.84076923076924,152.94615384615383,158.05153846153846,163.15692307692308,168.2623076923077,173.36769230769232,178.47307692307692,183.57846153846154,188.68384615384616,193.78923076923076,198.8946153846154,{"y":204,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.63,140.6723076923077,143.71461538461537,146.75692307692307,149.79923076923077,152.84153846153845,155.88384615384615,158.92615384615385,161.96846153846155,165.01076923076923,168.05307692307693,171.0953846153846,174.1376923076923,{"y":177.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,137.63,137.81230769230768,137.99461538461537,138.17692307692306,138.35923076923078,138.54153846153847,138.72384615384615,138.90615384615384,139.08846153846153,139.27076923076922,139.45307692307694,139.63538461538462,139.8176923076923,{"y":140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 91,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 97,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$204.00

Average Price Target$177.18

Lowest Price Target$140.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anupam Rama

J.P. Morgan

$177→$176

Buy

37.09%

Upside

Reiterated

02/17/26

Neurocrine post-earnings selloff overdone, says JPMorganNeurocrine post-earnings selloff overdone, says JPMorgan

Danielle Brill

Truist Financial

$169→$140

Buy

9.05%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$175

Buy

36.31%

Upside

Reiterated

02/17/26

Neurocrine (NBIX) Gets a Buy from Guggenheim

Mohit Bansal

Wells Fargo

$180→$175

Buy

36.31%

Upside

Reiterated

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NASDAQ: NBIX), Dexcom (NASDAQ: DXCM) and Icon (NASDAQ: ICLR)

Andrew Fein

H.C. Wainwright

$198→$192

Buy

49.56%

Upside

Reiterated

02/12/26

Neurocrine price target lowered to $192 from $198 at H.C. WainwrightNeurocrine price target lowered to $192 from $198 at H.C. Wainwright

Ami Fadia

Needham

$184→$185

Buy

44.10%

Upside

Reiterated

02/12/26

Neurocrine Biosciences: Durable Ingrezza Growth and Emerging Crenessity Ramp Support Buy Rating Despite Near-Term Cost Pressures

Myles Minter

William Blair

Buy

―

Reiterated

02/12/26

Buy Rating on Pullback: Solid Top-Line Growth, Ingrezza Strength, and Crenessity Blockbuster Potential Support Long-Term Upside

Cory Kasimov

Evercore ISI

$200

Buy

55.79%

Upside

Reiterated

02/12/26

Evercore ISI Keeps Their Buy Rating on Neurocrine (NBIX)

Akash Tewari

Jefferies

$174

Buy

35.54%

Upside

Reiterated

02/12/26

Neurocrine (NBIX) Receives a Buy from Jefferies

Paul Matteis

Stifel Nicolaus

$188

Buy

46.44%

Upside

Reiterated

02/12/26

Stifel Nicolaus Keeps Their Buy Rating on Neurocrine (NBIX)

Sean Laaman

Morgan Stanley

$175→$173

Hold

34.76%

Upside

Reiterated

02/12/26

Neurocrine price target lowered to $173 from $175 at Morgan StanleyNeurocrine price target lowered to $173 from $175 at Morgan Stanley

Laura Chico

Wedbush

$149→$151

Buy

17.62%

Upside

Reiterated

02/12/26

Wedbush Remains a Buy on Neurocrine (NBIX)

Phil Nadeau

TD Cowen

$200

Buy

55.79%

Upside

Reiterated

02/12/26

Neurocrine Biosciences: Durable Franchise Momentum and Pipeline Investment Support Buy Rating

Sumant Kulkarni

Canaccord Genuity

$164

Buy

27.75%

Upside

Reiterated

02/12/26

Canaccord Genuity Reaffirms Their Buy Rating on Neurocrine (NBIX)

Yigal Nochomovitz

Citi

$203→$204

Buy

58.90%

Upside

Reiterated

02/12/26

Neurocrine price target raised to $204 from $203 at CitiNeurocrine price target raised to $204 from $203 at Citi

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anupam Rama

J.P. Morgan

$177→$176

Buy

37.09%

Upside

Reiterated

02/17/26

Neurocrine post-earnings selloff overdone, says JPMorganNeurocrine post-earnings selloff overdone, says JPMorgan

Danielle Brill

Truist Financial

$169→$140

Buy

9.05%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$175

Buy

36.31%

Upside

Reiterated

02/17/26

Neurocrine (NBIX) Gets a Buy from Guggenheim

Mohit Bansal

Wells Fargo

$180→$175

Buy

36.31%

Upside

Reiterated

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NASDAQ: NBIX), Dexcom (NASDAQ: DXCM) and Icon (NASDAQ: ICLR)

Andrew Fein

H.C. Wainwright

$198→$192

Buy

49.56%

Upside

Reiterated

02/12/26

Neurocrine price target lowered to $192 from $198 at H.C. WainwrightNeurocrine price target lowered to $192 from $198 at H.C. Wainwright

Ami Fadia

Needham

$184→$185

Buy

44.10%

Upside

Reiterated

02/12/26

Neurocrine Biosciences: Durable Ingrezza Growth and Emerging Crenessity Ramp Support Buy Rating Despite Near-Term Cost Pressures

Myles Minter

William Blair

Buy

―

Reiterated

02/12/26

Buy Rating on Pullback: Solid Top-Line Growth, Ingrezza Strength, and Crenessity Blockbuster Potential Support Long-Term Upside

Cory Kasimov

Evercore ISI

$200

Buy

55.79%

Upside

Reiterated

02/12/26

Evercore ISI Keeps Their Buy Rating on Neurocrine (NBIX)

Akash Tewari

Jefferies

$174

Buy

35.54%

Upside

Reiterated

02/12/26

Neurocrine (NBIX) Receives a Buy from Jefferies

Paul Matteis

Stifel Nicolaus

$188

Buy

46.44%

Upside

Reiterated

02/12/26

Stifel Nicolaus Keeps Their Buy Rating on Neurocrine (NBIX)

Sean Laaman

Morgan Stanley

$175→$173

Hold

34.76%

Upside

Reiterated

02/12/26

Neurocrine price target lowered to $173 from $175 at Morgan StanleyNeurocrine price target lowered to $173 from $175 at Morgan Stanley

Laura Chico

Wedbush

$149→$151

Buy

17.62%

Upside

Reiterated

02/12/26

Wedbush Remains a Buy on Neurocrine (NBIX)

Phil Nadeau

TD Cowen

$200

Buy

55.79%

Upside

Reiterated

02/12/26

Neurocrine Biosciences: Durable Franchise Momentum and Pipeline Investment Support Buy Rating

Sumant Kulkarni

Canaccord Genuity

$164

Buy

27.75%

Upside

Reiterated

02/12/26

Canaccord Genuity Reaffirms Their Buy Rating on Neurocrine (NBIX)

Yigal Nochomovitz

Citi

$203→$204

Buy

58.90%

Upside

Reiterated

02/12/26

Neurocrine price target raised to $204 from $203 at CitiNeurocrine price target raised to $204 from $203 at Citi

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months

xxx

Success Rate

12/18 ratings generated profit

Average Return

+5.00%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +5.00% per trade.

1 Year

Laura ChicoWedbush

Success Rate

14/20 ratings generated profit

Average Return

+4.83%

reiterated a buy rating 8 days ago

Copying Laura Chico's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +4.83% per trade.

2 Years

xxx

Success Rate

19/26 ratings generated profit

Average Return

+12.31%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 73.08% of your transactions generating a profit, with an average return of +12.31% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

101

In the current month, NBIX has received 97 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 177.18.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $1.11 with a range of $0.06 to $1.61. The previous quarter’s EPS was $1.48. NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $768.37M with a range of $671.30M to $832.29M. The previous quarter’s sales results were $805.50M. NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year NBIX has Performed in-line its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 177.18.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine has 38.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy which is based on 20 buy ratings, 3 hold ratings and 0 sell ratings.

What is Neurocrine’s price target?

The average price target for Neurocrine is 177.18. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $204.00 ,the lowest forecast is $140.00. The average price target represents 38.01% Increase from the current price of $128.38.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Detailed List of Analyst Forecasts